T

TransMedics

Ex-vivo organ perfusion platform

Head of Clinical Command Operations

Full-TimeUpdated on 10/22/2026
$232.8k - $331.4k+ Bonus + Equity
Expert
Master's, MBA, PhD, MD
Andover, MA, USA
In Person
Medical, Clinical & Veterinary

About the job

Requirements
  • Active or prior clinical licensure or certification (MD, certified clinical perfusionist, critical care registered nurse, or equivalent), plus a master's degree in a clinical field, healthcare administration, or business.
  • 10+ years of progressive leadership in clinical services, field clinical operations, or clinical support within medical device, organ preservation, transplant, or a comparable time-critical clinical environment, including 5+ years at director level or above.
  • Direct experience in transplant, organ procurement, perfusion, or OPO operations, with working knowledge of OPTN/UNOS policy and the transplant ecosystem.
  • Proven success leading leaders and managing a large, geographically distributed, 24/7 on-call clinical workforce.
  • Working knowledge of FDA medical device regulations, including 21 CFR 820, complaint handling, and MDR.
  • Willingness to travel 20–30% to regional hubs, transplant centers, OPOs, and industry meetings.
Responsibilities
  • Work with the SVP to set the multi-year strategy and operating model for Clinical Services and the Clinical Command Center, aligned with corporate strategy.
  • Organize the operating model by organ and procedure type, including case protocols, staffing models, and service-level commitments to transplant centers and OPOs.
  • Partner with the Clinical Field Operations Lead on regional hubs, on-call rotations, surge capacity, and partnerships to guarantee 24/7/365 case acceptance.
  • Partner with Commercial, Medical Affairs, R&D, and Regulatory on new product launches, clinical studies, and service requirements for pipeline devices.
  • Own end-to-end Clinical Command Center performance, including case intake, triage, specialist assignment, device and consumable readiness, real-time monitoring, and clinical or technical escalation.
  • Establish and manage core KPIs for case acceptance, request-to-dispatch time, on-time arrival, device readiness and failure rates, protocol adherence, preservation time, case completion, and customer satisfaction.
  • Run daily huddles and weekly/monthly performance reviews, and drive root-cause analysis and corrective action on every compromised case.
  • Build a high-reliability culture with standardized playbooks, checklists, and decision support, including contingencies for transport failure and device malfunction.
  • Serve as senior escalation point on active cases and participate in the executive on-call rotation.
  • Lead and develop a Command Center team of clinical leaders overseeing team leads and specialists, including perfusionists, transplant-experienced nurses, and clinical device specialists.
  • Co-own workforce planning with the Head of Field Clinical Operations, including hiring tied to volume forecasts, territory design, on-call and travel policies, engagement, and retention.
  • Run an onboarding, credentialing, and recertification program so every specialist is proctored and signed off before independent case coverage.
  • Model clinical excellence and transparency, and foster an environment where employees feel comfortable speaking up to do what is right for the patient in a time-critical environment.
  • Partner with the Clinical Heads (CT and Abdominal), Quality, and Regulatory Affairs to ensure services meet FDA requirements, OPTN/UNOS policies, HRSA regulations, and hospital and OPO requirements.
  • Oversee case reviews, issue investigations, and complaint escalations with complete, timely documentation and closed-loop learning.
  • Partner with the training leader to develop and maintain training materials, and maintain audit readiness for regulators and clinical customers.
  • Own the operational relationship with supply chain and logistics partners, including device positioning, consumable inventory at regional hubs, charter and commercial transport, and reverse logistics.
  • Serve as business owner for Command Center technology with TMDX Digital and Infrastructure, including case management and dispatch, real-time device telemetry, scheduling and on-call tools, and performance dashboards.
  • Partner with IT, Data, and Engineering to advance remote monitoring, predictive staffing, and case analytics.
Desired Qualifications
  • Doctorate (DNP, PhD, MD/DO) or advanced business credential.
  • Experience with ex vivo organ perfusion or organ preservation technologies and associated clinical protocols.
  • Experience supporting commercial launch of a new device or indication in transplant centers.
  • Track record building or scaling a command center, dispatch, or case coordination function.
  • Lean, Six Sigma, or high-reliability organization (HRO) training.

About the company

TransMedics makes the Organ Care System (OCS), a portable platform that keeps donor organs alive outside the body by warm, oxygenated perfusion and continuous viability monitoring. The OCS circulates warmed, nutrient-rich blood through the organ, allowing surgeons to assess health in near-physiological conditions. Revenue comes from selling OCS consoles, disposable sets used per procedure, and the National OCS Program, which provides end-to-end organ retrieval and logistics services. It distinguishes itself by holding FDA approvals to preserve and assess hearts, lungs, and livers in the United States and by integrating hardware, consumables, and logistics to expand transplant opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 21% to $189.9 million, and guidance increased to $737-$757 million.
  • FDA approved ENHANCE Heart and DENOVO Lung IDEs in January-February 2026, advancing next-generation trials.
  • PAD Aviation closed July 6, 2026, opening pan-European transplant logistics contracts.

What critics are saying

  • Judge Sorokin partially denied dismissal July 21, 2026, forcing discovery in the fraud case.
  • CHOPS and kidney development burn cash while gross margin slipped to 60% in Q2 2026.
  • A bad ENHANCE or DENOVO safety signal in 2026-2027 would damage OCS credibility.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. warm-perfusion platform for hearts, lungs, and livers.
  • The National OCS Program bundles surgeons, logistics, aircraft, and disposables into a sticky ecosystem.
  • PAD Aviation extends TransMedics' logistics moat into Europe, copying the U.S. NOP playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short Term Disability
  • Long Term Disability
  • Health Savings Account/Flexible Spending Account
  • Dependent Care Flexible Spending Account
  • 401(k) Plan
  • Pet insurance
  • Employee Stock Purchase Plan
  • Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Oct 1st, 2026
TransMedics director buys $109K in stock amid 30% yearly decline

David Weill, a director at TransMedics Group, purchased 1,336 shares of common stock for approximately $109,000 on 11 September 2026, according to an SEC Form 4 filing. The purchase increased his direct holdings by 9% to 16,392 shares, valued at roughly $1.4 million. The transaction occurred as the stock recorded a one-year return of -30%. TransMedics, a commercial-stage medical technology company with a market capitalisation of $2.7 billion, develops the Organ Care System, a portable device that preserves and monitors donor organs for transplantation. The company reported trailing twelve-month revenues of $668.5 million and net income of $151.7 million. Management has guided for 22%-25% sales growth in 2026 as it expands internationally and develops new platforms.

Yahoo Finance
Sep 15th, 2026
TransMedics and SoFi stocks fall 28% and 34% but show strong buying potential

TransMedics Group and SoFi Technologies have declined 28% and 34% respectively over the past year, presenting potential buying opportunities despite broader market strength driven by tech giants. TransMedics, which developed the Organ Care System for transplants, faces near-term headwinds. Second-quarter revenue grew 21% year over year to $189.9 million, marking a slowdown from recent quarters. Adjusted earnings per share fell 52% to $0.44. However, the company is investing in expansion initiatives, including potential kidney transplant approval and a logistics network for greater control over the organ transplant cycle. These investments are pressuring current profits but could drive future growth. The OCS technology maintains organ temperature and blood supply during transport, addressing limitations of traditional cold storage methods. With a large addressable market remaining, the stock may offer value at current levels.

PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.